Technical Analysis for KIN - Kindred Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 9.85 -8.03% -0.86
KIN closed down 8.03 percent on Friday, January 18, 2019, on 9.35 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical KIN trend table...

Date Alert Name Type % Chg
Jan 18 MACD Bearish Signal Line Cross Bearish 0.00%
Jan 18 Volume Surge Other 0.00%
Jan 18 Multiple of Ten Bearish Other 0.00%
Jan 18 Below Lower BB Weakness 0.00%
Jan 18 Down 3 Days in a Row Weakness 0.00%
Jan 18 Down 4 Days in a Row Weakness 0.00%
Jan 18 Down 5 Days in a Row Weakness 0.00%
Jan 18 Gapped Down Weakness 0.00%
Jan 17 20 DMA Resistance Bearish -8.03%
Jan 17 BB Squeeze Ended Range Expansion -8.03%

Older signals for KIN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Kindred Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for pets. The company is pursuing small molecules and biologics that are in various stages of development for a range of indications in dogs, cats, and horses. Its products include CereKin, an oral interleukin-1 beta inhibitor for osteoarthritis pain and inflammation in dogs; AtoKin, a beef-flavored formulation of fexofenadine for atopic dermatitis in dogs; SentiKin, an oral analgesic formulation of flupirtine to manage post-operative pain in dogs and horses; KIND-007, an inhibitor of Bruton's tyrosine kinase; and KIND-006, an agent for gastrointestinal diseases in cats. The company also has a portfolio of other drugs and biologics under development, which comprise anti-IgE antibody for allergic and immune-mediated diseases; canine analog of Enbrel for inflammatory and autoimmune diseases; canine analog of Orencia for immune-mediated diseases; and KIND-504, a cancer vaccine. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.
Is KIN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 15.75
52 Week Low 7.55
Average Volume 156,293
200-Day Moving Average 11.9521
50-Day Moving Average 12.0732
20-Day Moving Average 11.033
10-Day Moving Average 11.166
Average True Range 0.5689
ADX 20.42
+DI 17.6889
-DI 36.5064
Chandelier Exit (Long, 3 ATRs ) 10.4533
Chandelier Exit (Short, 3 ATRs ) 11.3067
Upper Bollinger Band 11.8996
Lower Bollinger Band 10.1664
Percent B (%b) -0.18
BandWidth 15.709236
MACD Line -0.3473
MACD Signal Line -0.3017
MACD Histogram -0.0456
Fundamentals Value
Market Cap 274.19 Million
Num Shares 27.8 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -8.42
Price-to-Sales 0.00
Price-to-Book 2.41
PEG Ratio -0.15
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.68
Resistance 3 (R3) 10.68 10.42 10.54
Resistance 2 (R2) 10.42 10.21 10.41 10.49
Resistance 1 (R1) 10.13 10.08 10.28 10.13 10.45
Pivot Point 9.87 9.87 9.94 9.86 9.87
Support 1 (S1) 9.58 9.66 9.73 9.58 9.25
Support 2 (S2) 9.32 9.53 9.31 9.21
Support 3 (S3) 9.03 9.32 9.16
Support 4 (S4) 9.03